Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863860 | 0.94 | HRH3 (0.52) | HRH3 | |
| SCHEMBL10191862 | 0.93 | MEN1 (0.45) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL10191845 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL863954 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL7856596 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL7856898 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL7849634 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL7849312 | 0.92 | HRH3 (0.44) | HRH3MEN1KMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL864809 | 0.89 | HRH3 (0.45) | HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL864437 | 0.88 | HRH3 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010144571-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885MEN1 1150/4885KMT2A 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.